xFOREST Therapeutics Co., Ltd.
PrivateLast Round
Series A
Jan 24, 2025
Est. Valuation
$54.34M
Total Funding Raised
$13.16M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
xFOREST Therapeutics Co., Ltd. operates in Healthcare & Life Sciences and is based in Kyoto. Its latest recorded funding round was a Series A round in January 2025.
xFOREST Therapeutics Co., Ltd. is a biotechnology company that develops small molecule drug discovery platforms targeting RNA structures.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
xFOREST Therapeutics Co., Ltd. Comparables
Compare xFOREST Therapeutics Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Reborna Biosciences, Inc. | 88% | |
| Ribometrix | 87% | |
| Arrakis Therapeutics | 85% |
For institutional investors. Book with your work email.
xFOREST Therapeutics Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 24, 2025 | ||||
| Seed | Oct 6, 2020 | ||||
| Accelerator | Jan 8, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
xFOREST Therapeutics Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Open Network Lab | Accelerator |
| ANRI株式会社 | Seed |
| Miyako Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 28, 2026
Open roles increased to 4, 8x the trailing average.
- Aug 24, 2025
Grew 17% QoQ, from 18 to 21 employees.
For institutional investors. Book with your work email.
xFOREST Therapeutics Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about xFOREST Therapeutics Co., Ltd.'s valuation, stock price, and market status.
Is xFOREST Therapeutics Co., Ltd. a public or private company?
xFOREST Therapeutics Co., Ltd. is a private company.
What is the current stock price of xFOREST Therapeutics Co., Ltd.?
xFOREST Therapeutics Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks xFOREST Therapeutics Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is xFOREST Therapeutics Co., Ltd. worth (valuation)?
xFOREST Therapeutics Co., Ltd.'s valuation is estimated at $54.3M based on funding round data.
Can I buy xFOREST Therapeutics Co., Ltd. stock?
xFOREST Therapeutics Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was xFOREST Therapeutics Co., Ltd.'s last funding round?
xFOREST Therapeutics Co., Ltd.'s most recent funding round was Series A on January 24, 2025.
Who are the main investors in xFOREST Therapeutics Co., Ltd.?
Key investors in xFOREST Therapeutics Co., Ltd. include Miyako Capital.
Will xFOREST Therapeutics Co., Ltd. IPO soon?
No public IPO plans have been announced for xFOREST Therapeutics Co., Ltd..
How can I track xFOREST Therapeutics Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in xFOREST Therapeutics Co., Ltd.'s shares on secondary markets.